News & Updates

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Bintrafusp alfa, an investigational first-in-class bifunctional fusion protein, appears to induce response in patients with recurrent or metastatic cervical cancer, according to a phase II study.

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

Placement of two etonogestrel implants instead of one appears to suppress ovulation and increase plasma etonogestrel exposure, thereby increasing contraceptive effectiveness in HIV-positive women on efavirenz-based antiretroviral therapy (ART).

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

MIRV treatment effects sustained in PROC despite dose modifications

02 Aug 2024 by

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.

MIRV treatment effects sustained in PROC despite dose modifications

02 Aug 2024

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024 by

In a combined analysis of 3 phase III randomized trials presented at ESHRE 2024, a single dose of 150 µg or 100 µg of corifollitropin alfa is found to provide an ovarian response equivalent to daily doses of 300 IU or 297 IU of follitropin beta, respectively, during a single IVF cycle

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024 by

Women with ovarian hyperstimulation syndrome (OHSS) are at higher risk of experiencing postpartum haemorrhage, large birthweight, neonatal respiratory distress syndrome, and intraventricular haemorrhage, suggests a study presented at ESHRE 2024.

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024 by

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024 by

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024 by

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

MIRV treatment effects sustained in PROC despite dose modifications

MIRV treatment effects sustained in PROC despite dose modifications

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

Infertile women may benefit from oil-based contrast during HSG

Infertile women may benefit from oil-based contrast during HSG

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Is it unsafe to use GLP-1 RAs in early pregnancy?

Is it unsafe to use GLP-1 RAs in early pregnancy?

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer